HK184896A - Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine - Google Patents

Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine Download PDF

Info

Publication number
HK184896A
HK184896A HK184896A HK184896A HK184896A HK 184896 A HK184896 A HK 184896A HK 184896 A HK184896 A HK 184896A HK 184896 A HK184896 A HK 184896A HK 184896 A HK184896 A HK 184896A
Authority
HK
Hong Kong
Prior art keywords
tablet
composition
hydrophilic polymer
pseudoephedrine
loratadine
Prior art date
Application number
HK184896A
Other languages
English (en)
French (fr)
Inventor
P Cho Wing-Kee
A Vadino Winston
A Chaundry Imtiaz
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK184896A publication Critical patent/HK184896A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

  1. Pharmazeutische Zusammensetzung zur verzögerten Freisetzung, welche eine überzogene Tablette umfaßt, in welcher der Tablettenüberzug eine antihistaminisch wirksame Menge Loratadine oder 8-Chlor-6,11-dihydro-11-(4-piperidyliden)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin und ein hydrophiles Polymer umfaßt, und der Tablettenkern eine analgetisch wirksame Menge Ibuprofen, eine kongestionsvermindernd wirksame Menge Pseudoephedrin oder ein pharmazeutisch annehmbares Salz desselben und ein quellbares hydrophiles Polymer umfaßt und worin der Tablettenüberzug und der Tablettenkern weiter pharmazeutisch annehmbare Arzneimittelhilfsstoffe enthalten.
  2. Zusammensetzung des Anspruchs 1, bei welcher der Tablettenkern 10 bis 55% des Gewichts der überzogenen Tablette Ibuprofen, 3 bis 25% des Gewichts der überzogenen Tablette Pseudoephedrin oder ein pharmazeutisch annehmbares Salz desselben und 5 bis 15% des Gewichts des Tablettenkerns eines hydrophilen Polymers umfaßt.
  3. Zusammensetzung des Anspruchs 2, bei welcher der Tablettenkern weiter 10 bis 20% Füllstoff, 0 bis 5% Antihaftmittel, 0,25 bis 5% Gleitmittel und 0,5 bis 3% Bindemittel umfaßt.
  4. Zusammensetzung des Anspruchs 3, bei welcher das hydrophile Polymer ein Celluloseether ist, welcher aus Methylcellulose, Hydroxypropylcellulose, Hydroxymethylcellulose, Hydroxyethylcellulose, Carboxymethylcellulose, Carboxyethylcellulose und deren Gemischen ausgewählt ist, und der Füllstoff dibasisches Calciumphosphat oder das Dihydrat desselben, mikrokristalline Cellulose oder Lactose ist, das Antihaftmittel Siliziumdioxid oder Talk ist, das Gleitmittel Magnesiumstearat oder Stearinsäure ist und das Bindemittel Povidone oder Maisstärke ist.
  5. Zusammensetzung des Anspruchs 3, bei welcher das hydrophile Polymer Hydroxypropylmethylcellulose USP 2910 oder Hydroxypropylmethylcellulose USP 2208 mit einer Viskosität von 100000 cPs in einer 2%igen wäßrigen Lösung ist, der Füllstoff mikrokristalline Cellulose ist, das Gleitmittel Magnesiumstearat ist und das Bindemittel Povidone ist.
  6. Zusammensetzung des Anspruchs 1, bei welcher der Tablettenkern 120 mg Pseudoephedrinsulfat, 555 mg Ibuprofen 90%, 100 mg Hydroxypropylmethylcellulose USP 2208 mit einer Viskosität von 100000 cPs in einer 2%igen wäßrigen Lösung, 10 mg Povidone, 154 mg mikrokristalline Cellulose und 5 mg Magnesiumstearat umfaßt und bei welcher der Tablettenüberzug 5 mg Loratadine und 10 mg eines 5:1-Gemischs von Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 6 cPs in einer 2%igen wäßrigen Lösung und Polyethylenglykol mit einem Molekulargewicht von 300-6000 umfaßt.
  7. Zusammensetzung des Anspruchs 1, bei welcher der Tablettenkern 120 mg Pseudoephedrinsulfat, 555 mg Ibuprofen 90%, 150 mg Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 4000 cPs in einer 2%igen wäßrigen Lösung, 75 mg Povidone, 148,5 mg mikrokristalline Cellulose, 14 mg Siliziumdioxid und 5 mg Magnesiumstearat umfaßt und in welcher der Tablettenüberzug 5 mg Loratadine und 10 mg eines 5:1-Gemischs von Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 6 cPs in einer 2%igen wäßrigen Lösung und Polyethylenglykol mit einem Molekulargewicht von 300-6000 umfaßt.
  8. Pharmazeutische Zusammensetzung zur verzögerten Freisetzung, welche eine überzogene Tablette umfaßt, bei welcher der Tablettenüberzug eine antihistaminisch wirksame Menge Loratadine oder 8-Chlor-6,11-dihydro-11-(4-piperidyliden)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin und ein hydrophiles Polymer umfaßt, und der Tablettenkern eine analgetisch wirksame Menge Acetaminophen, eine kongestionsvermindernd wirksame Menge Pseudoephedrin oder ein pharmazeutisch annehmbares Salz desselben und ein quellbares hydrophiles Polymer umfaßt und worin der Tablettenüberzug und der Tablettenkern weiter pharmazeutisch annehmbare Arzneimittelhilfsstoffe enthalten.
  9. Zusammensetzung des Anspruchs 8, bei welcher der Tablettenkern 10 bis 65% des Gewichts der überzogenen Tablette Acetaminophen, 3 bis 35% des Gewichts der überzogenen Tablette Pseudoephedrin oder ein pharmazeutisch annehmbares Salz desselben und 5 bis 15% des Gewichts des Tablettenkerns eines hydrophilen Polymers umfaßt.
  10. Zusammensetzung des Anspruchs 9, bei welcher der Tablettenkern weiter 10 bis 20% Füllstoff, 0 bis 5% Antihaftmittel, 0,25 bis 5% Gleitmittel und 0 bis 3% Bindemittel umfaßt.
  11. Zusammensetzung des Anspruchs 9, bei welcher das hydrophile Polymer ein Celluloseether ist, welcher aus Methylcellulose, Hydroxypropylcellulose, Hydroxymethylcellulose, Hydroxyethylcellulose, Carboxymethylcellulose, Carboxyethylcellulose und deren Gemischen ausgewählt ist, und der Füllstoff dibasisches Calciumphosphat oder das Dihydrat desselben, mikrokristalline Cellulose oder Lactose ist und das Gleitmittel Magnesiumstearat oder Stearinsäure ist.
  12. Zusammensetzung des Anspruchs 11, bei welcher das hydrophile Polymer Hydroxypropylmethylcellulose USP 2910 oder Hydroxypropylmethylcellulose USP 2208 mit einer Viskosität von 100000 cPs in einer 2%igen wäßrigen Lösung ist, der Füllstoff dibasisches Calciumphosphatdihydrat ist und das Gleitmittel Magnesiumstearat und Stearinsäure ist.
  13. Zusammensetzung des Anspruchs 8, bei welcher der Tablettenkern 60 mg Pseudoephedrinsulfat, 555 mg Acetaminophen 90%, 48 mg Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 4000 cPs in einer 2%igen wäßrigen Lösung, 98 mg dibasisches Calciumphosphatdihydrat, 10 mg Stearinsäure und 4 mg Magnesiumstearat umfaßt und bei welcher der Tablettenüberzug 2,5 mg Loratadine und 5 mg eines 5:1-Gemischs von Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 6 cPs in einer 2%igen wäßrigen Lösung und Polyethylenglykol mit einem Molekulargewicht von 300-6000 umfaßt.
HK184896A 1989-05-03 1996-10-03 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine HK184896A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/346,687 US4990535A (en) 1989-05-03 1989-05-03 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine

Publications (1)

Publication Number Publication Date
HK184896A true HK184896A (en) 1996-10-11

Family

ID=23360584

Family Applications (1)

Application Number Title Priority Date Filing Date
HK184896A HK184896A (en) 1989-05-03 1996-10-03 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine

Country Status (13)

Country Link
US (2) US4990535A (de)
EP (2) EP0396404B1 (de)
JP (1) JPH066536B2 (de)
KR (1) KR940011246B1 (de)
AT (1) ATE101517T1 (de)
AU (1) AU628986B2 (de)
CA (1) CA2054752C (de)
DE (1) DE69006628T2 (de)
DK (1) DK0396404T3 (de)
ES (1) ES2062355T3 (de)
HK (1) HK184896A (de)
MX (1) MX9203278A (de)
WO (1) WO1990013295A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506198A (ja) * 1991-03-04 1994-07-14 ワーナー−ランバート・コンパニー 種々な剤形の非ステロイド性抗炎症剤の新規な塩／イオン対
JPH069382A (ja) * 1992-04-17 1994-01-18 Takeda Chem Ind Ltd 安定化された固型製剤およびその製造方法
ZA933725B (en) * 1992-05-28 1993-12-15 Elan Corp Plc Tablet formulation
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
EP0674527A1 (de) * 1992-12-21 1995-10-04 The Procter & Gamble Company Verwendung von s(+) antipoden von analgetika zur herstellung einer zusammensetzung zur behandlung von atemwegserkrankungen
ES2107235T3 (es) * 1993-06-14 1997-11-16 Janssen Pharmaceutica Nv Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
DK0812195T3 (da) * 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
DE69734060T2 (de) * 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
EP0811374A1 (de) 1996-05-29 1997-12-10 Pfizer Inc. Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
CO4910128A1 (es) * 1996-10-31 2000-04-24 Schering Corp Tratamiento del asma y compuestos utiles para este trata- miento ta combinacion y un kit de esta combinacion
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
AU776837B2 (en) * 1997-02-07 2004-09-23 Sunovion Pharmaceuticals Inc. Lactose-free non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
WO1998036738A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
JP4344405B2 (ja) * 1997-08-26 2009-10-14 アベンティス・ファーマスーティカルズ・インコーポレイテッド ピペリジノアルカノール−鬱血除去剤の組合せ用医薬組成物
CA2325014C (en) * 1998-07-10 2002-05-28 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine oral compositions
PE20001070A1 (es) * 1998-09-10 2000-10-19 Schering Corp Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
KR100505899B1 (ko) * 1999-02-23 2005-08-01 주식회사유한양행 로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US6267986B1 (en) 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US6613357B2 (en) * 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
DE10003757A1 (de) * 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
EP1276502A1 (de) * 2000-04-14 2003-01-22 J-Med Pharmaceuticals, Inc. Einzeldosis antihistamin/dekongestivum formulierungen zur behandlung von rhinitis
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
US20020094345A1 (en) 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2434169C (en) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Spaced drug delivery system
PL364178A1 (en) * 2001-01-26 2004-12-13 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
AU2002241956A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20020183305A1 (en) * 2001-01-26 2002-12-05 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
DK1355644T3 (da) * 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2443632C (en) * 2001-04-10 2011-05-03 Sun Pharmaceutical Industries Limited Timed pulse release composition
JP2004532868A (ja) * 2001-05-25 2004-10-28 シェーリング　コーポレイション アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用
CN1518448A (zh) * 2001-06-20 2004-08-04 ���鹫˾ 用于治疗鼻充血和鼻塞的抗组胺剂
JP2005515966A (ja) * 2001-07-06 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002335770B2 (en) * 2001-09-21 2005-08-18 Merck Sharp & Dohme Corp. Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
NZ532096A (en) * 2001-09-28 2006-10-27 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US20040142903A1 (en) * 2003-01-16 2004-07-22 Par Pharmaceutical Inc. Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN100379408C (zh) * 2003-07-28 2008-04-09 马林克罗特公司 改进的硬脂酸盐组合物及制备方法
CA2540308C (en) 2003-09-26 2013-08-06 Alza Corporation Drug coating providing high drug loading and methods for providing the same
EP1680189A2 (de) * 2003-11-05 2006-07-19 Schering Corporation Kombinationen von lipidmodulierenden mitteln mit substituierten azetidinonen zur behandlung von vaskularen erkrankungen
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
WO2007143158A2 (en) 2006-06-01 2007-12-13 Schering-Plough Healthcare Products, Inc. Sustained release pharmaceutical formulation comprising phenylephrine
RU2008151945A (ru) * 2006-06-01 2010-07-20 Шеринг Корпорейшн (US) Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
ES2590604T3 (es) * 2008-01-04 2016-11-22 Schabar Research Associates Llc Composición que comprende un analgésico y un antihistamínico
US20130115250A1 (en) * 2009-05-13 2013-05-09 Wyeth Llc Burst Drug Release Compositions
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
JP5752578B2 (ja) * 2011-12-09 2015-07-22 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド 鼻炎治療のための単一投与抗ヒスタミン薬／鬱血除去薬製剤
EP2727592A1 (de) * 2012-11-05 2014-05-07 Kücükgüzel, Sükriye Güniz Kombination aus Desloratadin und Paracetamol
HRP20220112T1 (hr) 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
US20170105996A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
KR20230051164A (ko) 2020-07-15 2023-04-17 샤바르 리서치 어소시에이츠 엘엘씨 급성 통증의 치료 및 속쓰림의 중증도 및/또는 위험의 감소를 위한 이부프로펜 및 파모티딘으로 구성된 단위 경구 투여 조성물
CR20230109A (es) 2020-07-30 2023-05-11 Faes Farma Sa Sistema de liberación de fármacos descongestivos y bilastina

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
HU194864B (en) 1984-02-15 1988-03-28 Schering Corp Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4871733A (en) * 1984-04-09 1989-10-03 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions

Also Published As

Publication number Publication date
KR920700033A (ko) 1992-02-19
EP0396404A1 (de) 1990-11-07
KR940011246B1 (ko) 1994-12-03
MX9203278A (es) 1992-07-01
AU5664890A (en) 1990-11-29
US4990535A (en) 1991-02-05
JPH066536B2 (ja) 1994-01-26
JPH04501425A (ja) 1992-03-12
EP0396404B1 (de) 1994-02-16
ES2062355T3 (es) 1994-12-16
ATE101517T1 (de) 1994-03-15
US5100675A (en) 1992-03-31
WO1990013295A1 (en) 1990-11-15
DK0396404T3 (da) 1994-03-14
CA2054752C (en) 1996-12-31
AU628986B2 (en) 1992-09-24
CA2054752A1 (en) 1990-11-04
EP0471009A1 (de) 1992-02-19
DE69006628D1 (de) 1994-03-24
DE69006628T2 (de) 1994-05-26

Similar Documents

Publication Publication Date Title
EP0396404B1 (de) Pharmazeutische Zusammensetzung, enthaltend Loratadin, Ibuprofen und Pseudoephedrin
US4601894A (en) Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
KR101234940B1 (ko) 안정한 서방출형의 경구 투여용 조성물
AU676229B2 (en) Stable extended release oral dosage composition
EP0103636B1 (de) Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler störungen
US4829064A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
DE69836424T2 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
US4975426A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
AU703242B2 (en) Film coated tablet of paracetamol and domperidone
EP0348683A1 (de) Ibuprofen in Kombination mit einem Piperidinylalkanolantihistaminikum enthaltenden Arzneimittel
NZ244564A (en) Pharmaceutical composition for treating pain of chronic medical conditions comprising ibuprofen and codeine in a ratio range of 15-25:1
US4657757A (en) Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
JP3018160B2 (ja) 月経困難症及び／又は月経前症候群の軽減用薬剤
GB2281205A (en) Oral opioid analgesic
EP2029114A2 (de) Pharmazeutische zusammensetzungen für die dauerhafte freisetzung von phenyeprhin
WO2011000518A1 (en) Pharmaceutical composition comprising desloratadine
EP0182569B1 (de) Anwendung von 1,6-Dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4H-pyrido[1,2-a]pyrimidin-3-carboxamid zur Vorbeugung und Behandlung von Gastrointestinalschäden
KR101199654B1 (ko) 안정한 서방출형의 경구 투여용 조성물
HK1010687B (en) Film coated tablet of paracetamol and domperidone

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)